FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.9.1  |  FHIR Version n/a  User: [n/a]

900000000000526001: REPLACED BY association reference set (foundation metadata concept)

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2002. Module: SNOMED CT model component module (core metadata concept)

Descriptions:

Id Description Lang Type Status Case? Module
900000000001156010 REPLACED BY association reference set (foundation metadata concept) en Fully specified name Active Entire term case sensitive (core metadata concept) SNOMED CT model component module (core metadata concept)
900000000001157018 REPLACED BY association reference set en Synonym (core metadata concept) Active Entire term case sensitive (core metadata concept) SNOMED CT model component module (core metadata concept)

23379 members. Search Members:

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
REPLACED BY association reference set (foundation metadata concept) Is a Historical association reference set (foundation metadata concept) true Inferred relationship Some
Members targetComponentId
Myeloid neoplasm with beta-type platelet-derived growth factor receptor gene rearrangement Myeloid/lymphoid neoplasm with PDGFRB rearrangement
Myeloproliferativ sygdom Myeloid proliferation
Myelosclerosis Myelofibrosis
Myelosclerosis with myeloid metaplasia Primary myelofibrosis
Myocardial infarction clinical management plan Myocardial infarction clinical management plan (record artifact)
Myokardit, ikke nærmere specificeret Myocarditis
Myocarditis NOS Myocarditis
myom Myoma
Myometrial hyperplasia Hyperplasia of myometrium (disorder)
Myotenontoplasty Myotenoplasty (procedure)
Myotenoplasty of hand Myotenoplasty (procedure)
muskelspændingsteknik Muscle energy technique (procedure)
Myovirus group Family Myoviridae (organism)
Myringoplasty NEC Myringoplasty (procedure)
Myringoplasty NEC Myringoplasty (procedure)
myringotomi inklusive aspiration i universel anæstesi Myringotomy and drainage of middle ear (procedure)
N-b-bis (2-chloroethyl)-2-naphthylamine Chlornaphazine (substance)
N0-stadium American Joint Committee on Cancer cN0 (qualifier value)
N1: Metastasering til 1-3 lymfeknuder American Joint Committee on Cancer cN1 (qualifier value)
N1: Metastasering til 1-6 perigastriske lymfeknuder American Joint Committee on Cancer cN1 (qualifier value)
N1: Metastasering til en enkelt ipsilateral lymfeknude, største udstrækning under 3 cm American Joint Committee on Cancer cN1 (qualifier value)
N1: Metastasering til en enkelt lymfeknude American Joint Committee on Cancer cN1 (qualifier value)
N1: Metastasering til en enkelt lymfeknude, største udstrækning under 2 cm American Joint Committee on Cancer cN1 (qualifier value)
N1: Metastasering til en enkelt lymfeknude, største udstrækning 2 cm eller derunder American Joint Committee on Cancer cN1 (qualifier value)
N1: metastasering til ipsilaterale peribronkiale og/eller ipsilaterale hilære lymfeknuder, inklusive intrapulmonale lymfeknuder, involveret ved direkte spredning af primærtumoren American Joint Committee on Cancer cN1 (qualifier value)
N1: Metastasering til perirektal(e) lymfeknude(r) American Joint Committee on Cancer cN1 (qualifier value)
N1: Metastasering til regional(e) lymfeknude(r) American Joint Committee on Cancer cN1 (qualifier value)
N1: Metastasering til ufikseret(-de) ipsilateral(e) aksillymfeknude(r) American Joint Committee on Cancer cN1 (qualifier value)
N1: metastase med en lymfeknudeudfyldning under 2 cm i største udstrækning og 5 eller færre positive noduli, ingen over 2 cm i største udstrækning American Joint Committee on Cancer cN1 (qualifier value)
N1: metastase i pelvin eller ingvinal lymfeknude American Joint Committee on Cancer cN1 (qualifier value)
N1: Metastasering til regionale lymfeknuder American Joint Committee on Cancer cN1 (qualifier value)
N1: Unilateral metastasering til lymfeknude(r), største udstrækning over 6 cm, over supraklavikulære fossa American Joint Committee on Cancer cN1 (qualifier value)
N1a: 1-3 noduli involveret American Joint Committee on Cancer cN1a (qualifier value)
N1a: Metastasering til ipsilateral(e) cervikal(e) lymfeknude(r) American Joint Committee on Cancer cN1a (qualifier value)
N1a: Metastasering til enkelt regional lymfeknude American Joint Committee on Cancer cN1a (qualifier value)
N1a: Kun mikrometastase, ingen over 0,2 cm i største udstrækning American Joint Committee on Cancer cN1a (qualifier value)
N1b: 4-7 noduli involveret American Joint Committee on Cancer cN1b (qualifier value)
N1b: Metastasering til bilateral(e), midterlinje- eller kontralateral(e) cervikal(e) eller mediastinal(e) lymfeknude(r) American Joint Committee on Cancer cN1b (qualifier value)
N1b: Metastasering til multiple regionale lymfeknuder American Joint Committee on Cancer cN1b (qualifier value)
N1b: Metastasering til lymfeknude(r), alle med største udstrækning over 0,2 cm American Joint Committee on Cancer cN1b (qualifier value)
N1c: mere end 7 noduli involveret American Joint Committee on Cancer cN1c (qualifier value)
N2-stadium American Joint Committee on Cancer cN2 (qualifier value)
N2: Bilateral metastasering til lymfeknude(r), største udstrækning over 6 cm, over supraklavikulære fossa American Joint Committee on Cancer cN2 (qualifier value)
N2: Metastasering til 4 eller flere lymfeknuder American Joint Committee on Cancer cN2 (qualifier value)
N2: Metastasering til 7-15 perigastriske lymfeknuder American Joint Committee on Cancer cN2 (qualifier value)
N2: Metastase i en ipsilateral lymfeknude, største udstrækning > 3 cm, men < 6 cm, eller i multiple ipsilaterale lymfeknuder, ingen > 6 cm i største udstrækning, eller i bilaterale eller kontralaterale lymfeknuder, ingen > 6 cm i største udstrækning American Joint Committee on Cancer cN2 (qualifier value)
N2: Metastasering til en enkelt lymfeknude, største udstrækning over 2 cm, men ikke over 5 cm, eller multiple lymfeknuder, ingen over 5 cm i største udstrækning American Joint Committee on Cancer cN2 (qualifier value)
N2: metastasering til ipsilateral(e) mediastinal(e) og/eller subkarinal(e) lymfeknude(r) American Joint Committee on Cancer cN2 (qualifier value)
N2: Metastasering til mere end én regional lymfeknude American Joint Committee on Cancer cN2 (qualifier value)
N2: Metastasering til ipsilateral(e) aksillymfeknude(r) fæstnet til hinanden eller til andre strukturer American Joint Committee on Cancer cN2 (qualifier value)
N2: Metastasering til unilateral(e) intern(e) iliakal(e) og/eller ingvinal(e) lymfeknude(r) American Joint Committee on Cancer cN2 (qualifier value)
N2: metastase med en lymfeknudeudfyldning over 2 cm, men ikke over 5 cm i største udstrækning eller med mere end 5 positive noduli, ingen over 5 cm, eller tegn på ekstranodal spredning af tumor American Joint Committee on Cancer cN2 (qualifier value)
N2a: Metastasering til en enkelt ipsilateral lymfeknude, største udstrækning over 3 cm, men under 6 cm American Joint Committee on Cancer cN2a (qualifier value)
N2b: Metastasering til multiple ipsilaterale lymfeknuder, ingen over 6 cm i største udstrækning American Joint Committee on Cancer cN2b (qualifier value)
N2c: Metastasering til bilaterale eller kontralaterale lymfeknuder, ingen over 6 cm i største udstrækning American Joint Committee on Cancer cN2c (qualifier value)
N3-stadium American Joint Committee on Cancer cN3 (qualifier value)
N3: Metastasering til over 15 perigastriske lymfeknuder American Joint Committee on Cancer cN3 (qualifier value)
N3: Metastasering til en lymfeknude, største udstrækning over 5 cm American Joint Committee on Cancer cN3 (qualifier value)
N3: Metastasering til en lymfeknude, største udstrækning over 6 cm American Joint Committee on Cancer cN3 (qualifier value)
N3: Metastasering til kontralateral(e) mediastinal(e), kontralateral(e) hilær(e), ipsilateral(e) eller kontralateral(e) skalenerlymfeknude(r) eller supraklavikulær(e) lymfeknude(r) American Joint Committee on Cancer cN3 (qualifier value)
N3: Metastasering til lymfeknude(r) American Joint Committee on Cancer cN3 (qualifier value)
N3: Metastasering til ipsilateral(e) intern(e) lymfeknude(r) i mamma American Joint Committee on Cancer cN3 (qualifier value)
N3: metastase med en lymfeknudeudfyldning over 5 cm i største udstrækning American Joint Committee on Cancer cN3 (qualifier value)
N3a: udstrækning over 6 cm American Joint Committee on Cancer cN3a (qualifier value)
N3b: spredning til supraklavikulære fossa American Joint Committee on Cancer cN3b (qualifier value)
NAD(P)H dehydrogenase (FMN) NAD(P)H dehydrogenase (quinone)
NX-stadium American Joint Committee on Cancer cNX (qualifier value)
Nabothian follicles on cervix Mucous retention cyst of cervix uteri (disorder)
Nabothian follicles on cervix Mucous retention cyst of cervix uteri (disorder)
Nabothske follikler på cervix Mucous retention cyst of cervix uteri (disorder)
nabumeton 500 mg dispergibel tablet Nabumetone 2.5 mg/mL oral solution
Negledystrofi som følge af giftigt kemikalie Nail dystrophy caused by chemical
Nail flap Flap (substance)
Nairobi sheep disease serogroup Nairobi sheep disease virus
Nape of neck flap Flap (substance)
naphazolinhydrochlorid + polyvinylalkohol + zinksulfat 0,02 % wt/vol/0,25 % wt/vol/0,25 % wt/vol dråber Product containing only naphazoline and polyvinyl alcohol and zinc sulfate (medicinal product)
naproxen 200 mg + pseudoephedrin 120 mg tablet med modificeret udløsning Product containing only naproxen and pseudoephedrine (medicinal product)
Naproxen 200mg/pseudoephedrine 120mg prolonged-release oral tablet Product containing only naproxen and pseudoephedrine (medicinal product)
naproxen 500 mg tablet med modificeret udløsning Product containing precisely naproxen 500 milligram/1 each gastro-resistant oral tablet (clinical drug)
naproxennatrium 220 mg + pseudoephedrin 120 mg tablet med modificeret udløsning Product containing only naproxen and pseudoephedrine (medicinal product)
Naproxen sodium 220mg/pseudoephedrine 120mg prolonged-release oral tablet Product containing only naproxen and pseudoephedrine (medicinal product)
Naproxen sodium 375mg gastro-resistant oral tablet Product containing precisely naproxen 375 milligram/1 each gastro-resistant oral tablet (clinical drug)
naproxennatrium 375 mg tablet med modificeret udløsning Product containing precisely naproxen 375 milligram/1 each gastro-resistant oral tablet (clinical drug)
Naproxen sodium 500mg gastro-resistant oral tablet Naproxen only product in oral dose form
naproxennatrium 500 mg tablet med modificeret udløsning Naproxen only product in oral dose form
Snæver åben vinkel Narrow angle (finding)
fund vedr. næsehulen og sinus ethmoidales udtrykt ved TNM-systemet American Joint Committee on Cancer allowable value
Nasal diagnostisk laryngoskopi Nasal laryngoscopy
Nasal flap Flap (substance)
Nasal sinus operations NOS Operation on accessory sinus
Nasal sinus operations NOS Operation on accessory sinus
Nasal sinusectomy - other Accessory sinus excision
Nasal sinusectomy - other Accessory sinus excision
Nasal sinusotomy - other Operation on accessory sinus
Nasal sinusotomy - other Operation on accessory sinus
Nasalis flap Flap (substance)
Nasolabial flap Flap (substance)
Nasopharyngoscopy: [diagnostic NEC] or [NEC] Nasopharyngoscopy
fund vedr. pars nasalis pharyngis udtrykt ved TNM-systemet American Joint Committee on Cancer allowable value
National gov't. officer NOS National government officer (occupation)
National government general administrator NOS Government administrator

Start Previous Page 120 of 234 Next End

Reference Sets

Reference set descriptor

Back to Start